Thalidomide-rituximab was administered to 25 symptomatic patients (20 previously untreated) with Waldenstrom macroglobulinemia. The overall response rate was 72%, and the median time-to-progression for responders was 38 months.
Among patients who undergo screening and are diagnosed with prostate cancer, there is a dichotomy between those who are diagnosed after their initial screening (prevalent cases) and those who have cancer detected after subsequent screenings (incident cases).
A new regimen (fluorouracil, leucovorin, oxaliplatin, and docetaxel [FLOT]) was tested in a phase II trial in 54 patients with gastric or gastro-esophageal cancer. Response rates were comparable, or perhaps even a little better than those published for other combinations; the toxicity profile appears favorable.
The JUPITER trial causes a stir; ACP practice guideline for antidepressant use; testosterone for low libido; continued shortage of Hib vaccine; FDA Actions.
Eltabbakh retrospectively reviewed women presenting with clinical stage I endometrial cancer (according to the 1988 FIGO staging) at the University of Vermont.
